Masayo Ogawa

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

Christophe Legendre, Christoph Licht, Petra Muus et al. · New England Journal of Medicine · 2013 · 1.6K citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial

Fádi Fakhouri, Maryvonne Hourmant, Josep M. Campistol et al. · American Journal of Kidney Diseases · 2016 · 308 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome

Larry A. Greenbaum, Marc Fila, Gianluigi Ardissino et al. · Kidney International · 2016 · 294 citations · Full text

Medicine, Pediatrics, Pharmacotherapy +14

Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS

Roxanne Cofiell, Anjli Kukreja, Krystin Bedard et al. · Blood · 2015 · 199 citations · Full text

Medicine, Cardiology, Nephrology +16

Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome

Franz Schaefer, Gianluigi Ardissino, Gema Ariceta et al. · Kidney International · 2018 · 179 citations

Medicine, Genetics, Nephrology +14